Acasti Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Acasti Pharma has a total shareholder equity of $59.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $69.7M and $10.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$19.41m |
| Equity | US$59.36m |
| Total liabilities | US$10.35m |
| Total assets | US$69.72m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: L8S's short term assets ($20.4M) exceed its short term liabilities ($2.6M).
Long Term Liabilities: L8S's short term assets ($20.4M) exceed its long term liabilities ($7.8M).
Debt to Equity History and Analysis
Debt Level: L8S is debt free.
Reducing Debt: L8S has no debt compared to 5 years ago when its debt to equity ratio was 43.5%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: L8S has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: L8S has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 9.2% each year.